Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
HK Reddel, LB Bacharier, ED Bateman… - American journal of …, 2022 - atsjournals.org
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …
updated evidence-based strategy for asthma management and prevention, which can be …
[HTML][HTML] Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
ML Levy, LB Bacharier, E Bateman, LP Boulet… - NPJ primary care …, 2023 - nature.com
Abstract The Global Initiative for Asthma (GINA) was established in 1993 by the World
Health Organization and the US National Heart Lung and Blood Institute to improve asthma …
Health Organization and the US National Heart Lung and Blood Institute to improve asthma …
Albuterol–budesonide fixed-dose combination rescue inhaler for asthma
A Papi, BE Chipps, R Beasley… - … England Journal of …, 2022 - Mass Medical Soc
Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …
The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review
M Stolbrink, H Thomson, RM Hadfield… - The Lancet Global …, 2022 - thelancet.com
Background Asthma and chronic obstructive pulmonary disease (COPD) cause a
considerable burden of morbidity and mortality in low-income and middle-income countries …
considerable burden of morbidity and mortality in low-income and middle-income countries …
Asthma management in low and middle income countries: case for change
Asthma is the most common noncommunicable disease in children, and among the most
common in adults. The great majority of people with asthma live in low and middle income …
common in adults. The great majority of people with asthma live in low and middle income …
[HTML][HTML] Diagnosis and management of asthma in children
J Martin, J Townshend, M Brodlie - BMJ Paediatrics Open, 2022 - ncbi.nlm.nih.gov
Asthma is the the most common chronic respiratory condition of childhood worldwide, with
around 14% of children and young people affected. Despite the high prevalence, paediatric …
around 14% of children and young people affected. Despite the high prevalence, paediatric …
[HTML][HTML] Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised …
Background Stepwise intensification of inhaled corticosteroids (ICS) is routine for severe
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
ED Bateman, DB Price, HC Wang… - European …, 2022 - Eur Respiratory Soc
Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …
and associated asthma-related clinical outcomes in patients with asthma, we assessed …
SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
Introduction Globally, individuals with asthma tend to overrely on short-acting β 2-agonists
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …
Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program
CI Bloom, C Cabrera, S Arnetorp, K Coulton, C Nan… - Advances in …, 2020 - Springer
Introduction Patients with asthma typically increase short-acting β 2-agonists (SABA) use
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …